Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rubitecan in Recurrent Ovarian or Primary Peritoneal Cancer
NCT00006267Phase 2Withdrawn
- Sponsor
- GOG Foundation
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in ovarian cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoint: Antitumor Activity. Status: withdrawn.
02
Drugs
rubitecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00006267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006267.